Dermatitis Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Description
Growth Factors of Dermatitis Drugs Market
The dermatitis drugs market size was valued at USD 6097.4 million in 2018, and the market is now projected tgrow USD 20919.4 million in 2032, exhibiting a CAGR of 8.9% during the forecast period of 2019-2032.
The dermatitis drugs market faced some changes due tthe COVID-19 pandemic, with the restrictions that affected diagnostics and treatment of patients. Closures occurred in many dermatology clinics due twhich patients have access tspecialized care and treatment only in the short term. The addition of new dermatitis drugs was another area which suffered from delayed clinical trials, which delayed the introduction of innovative therapies. However, the use of telemedicine and remote consultations was able tserve some as an answer tsustaining this paradigm. Over time the market is gradually regrowing and has been fueled by the growing awareness of more intricate dermatological procedures amongst patients.
One major factor that can be considered in the dermatitis drugs market today is the high fragmentation of the market hence; there are several manufacturers whdeal with the production of generic drugs. Dupilumab sold under the brand name Dupixent by Regeneron Pharmaceuticals and Sanofi has been tremendously transformed dermatitis treatment due tefficacy as well as emerging approval. This interleukin-4 inhibitor has now emerged as one of the most common treatments for curing dermatitis symptoms. Overall, Dupixent for the year 2018 touched about US$ 922 million in sales. The outcome of the drug points tthe progression towards more effective therapies in dermatitis market.
Demand for dermatitis drugs is growing because of the progress in biologics and other targeted agents like Dupixent. Twmajor trends are discernible at the present, one being that of a growing interest at the field of pharmacokinetics personalized medicine the second being that connected with the appearance of biologic products that target certain immune response. There is a growing interest in skin diseases and their advancement’s effects on the quality of life, which creates the need for efficient treatment. The market is alsexperiencing an increase in the use of topical corticosteroids and other improved formulations of recently developed molecules. Furthermore, telemedicine, and other digital solutions are improving outcomes of patient monitoring and disease management.
Comprehensive Analysis of Dermatitis Drugs Market
The dermatitis drugs market growth is rising at an exponential rate due tits market segmentation. This market expansion rightly presents a detailed local analysis based on the forces such as supply and demand which define the industry. These segmentations are methodically segregated by drug class, by disease indication, by distribution channel, and by geography. By drug class include calcineurin inhibitors, PDE4 inhibitors, corticosteroids, biologics, and others. By disease indication include atopic dermatitis, contact dermatitis and others. By distribution channel include hospital pharmacy, retail pharmacy, and online pharmacy. By geography include North America, Europe, Asia Pacific, and rest of world.
The North America region lead the dermatitis drugs market share by benefitting a market size of USD 3149.7 million in 2018 due tits advanced healthcare infrastructure.
The top players have a significant responsibility in the healthcare industry for confirming industrial prospectus growth and determining the market trends. These players include, Valeant Pharmaceuticals, Astellas Pharma US, Inc., Pfizer, Inc., Mylan, Bayer AG, Allergan, LEO Pharma, Regeneron Pharmaceuticals, Inc., and Anacor Pharmaceuticals, Inc. these market players provide a level-playing competitive landscape.
In March 2020, Valeant Pharmaceuticals (now Bausch Health Companies) launched a new topical treatment for eczema, expanding its dermatology portfolio.
Segmentation Table
ATTRIBUTE DETAILS
Drug Class
Calcineurin Inhibitors
PDE4 Inhibitors
Corticosteroids
Biologics
Others
By Disease Indication
Atopic Dermatitis
Contact Dermatitis
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography
North America (USA and Canada)
Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
Rest of World
The dermatitis drugs market size was valued at USD 6097.4 million in 2018, and the market is now projected tgrow USD 20919.4 million in 2032, exhibiting a CAGR of 8.9% during the forecast period of 2019-2032.
The dermatitis drugs market faced some changes due tthe COVID-19 pandemic, with the restrictions that affected diagnostics and treatment of patients. Closures occurred in many dermatology clinics due twhich patients have access tspecialized care and treatment only in the short term. The addition of new dermatitis drugs was another area which suffered from delayed clinical trials, which delayed the introduction of innovative therapies. However, the use of telemedicine and remote consultations was able tserve some as an answer tsustaining this paradigm. Over time the market is gradually regrowing and has been fueled by the growing awareness of more intricate dermatological procedures amongst patients.
One major factor that can be considered in the dermatitis drugs market today is the high fragmentation of the market hence; there are several manufacturers whdeal with the production of generic drugs. Dupilumab sold under the brand name Dupixent by Regeneron Pharmaceuticals and Sanofi has been tremendously transformed dermatitis treatment due tefficacy as well as emerging approval. This interleukin-4 inhibitor has now emerged as one of the most common treatments for curing dermatitis symptoms. Overall, Dupixent for the year 2018 touched about US$ 922 million in sales. The outcome of the drug points tthe progression towards more effective therapies in dermatitis market.
Demand for dermatitis drugs is growing because of the progress in biologics and other targeted agents like Dupixent. Twmajor trends are discernible at the present, one being that of a growing interest at the field of pharmacokinetics personalized medicine the second being that connected with the appearance of biologic products that target certain immune response. There is a growing interest in skin diseases and their advancement’s effects on the quality of life, which creates the need for efficient treatment. The market is alsexperiencing an increase in the use of topical corticosteroids and other improved formulations of recently developed molecules. Furthermore, telemedicine, and other digital solutions are improving outcomes of patient monitoring and disease management.
Comprehensive Analysis of Dermatitis Drugs Market
The dermatitis drugs market growth is rising at an exponential rate due tits market segmentation. This market expansion rightly presents a detailed local analysis based on the forces such as supply and demand which define the industry. These segmentations are methodically segregated by drug class, by disease indication, by distribution channel, and by geography. By drug class include calcineurin inhibitors, PDE4 inhibitors, corticosteroids, biologics, and others. By disease indication include atopic dermatitis, contact dermatitis and others. By distribution channel include hospital pharmacy, retail pharmacy, and online pharmacy. By geography include North America, Europe, Asia Pacific, and rest of world.
The North America region lead the dermatitis drugs market share by benefitting a market size of USD 3149.7 million in 2018 due tits advanced healthcare infrastructure.
The top players have a significant responsibility in the healthcare industry for confirming industrial prospectus growth and determining the market trends. These players include, Valeant Pharmaceuticals, Astellas Pharma US, Inc., Pfizer, Inc., Mylan, Bayer AG, Allergan, LEO Pharma, Regeneron Pharmaceuticals, Inc., and Anacor Pharmaceuticals, Inc. these market players provide a level-playing competitive landscape.
In March 2020, Valeant Pharmaceuticals (now Bausch Health Companies) launched a new topical treatment for eczema, expanding its dermatology portfolio.
Segmentation Table
ATTRIBUTE DETAILS
Drug Class
Calcineurin Inhibitors
PDE4 Inhibitors
Corticosteroids
Biologics
Others
By Disease Indication
Atopic Dermatitis
Contact Dermatitis
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography
North America (USA and Canada)
Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
Rest of World
Table of Contents
138 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of major dermatitis types by key countries, 2018
- 4.2. Recent industry developments such as mergers & acquisitions
- 4.3. Pipeline analysis
- 4.4. Patent landscape
- 4.5. Reimbursement scenario by key countries
- 4.6. Regulatory scenario for key countries
- 5. Global Dermatitis Drugs Market Analysis, Insights and Forecast, 2014-2025
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Drug Class
- 5.2.1. Calcineurin Inhibitors
- 5.2.2. PDE4 Inhibitors
- 5.2.3. Corticosteroids
- 5.2.4. Biologics
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast – By Disease Indication
- 5.3.1. Atopic Dermatitis
- 5.3.2. Contact Dermatitis
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacy
- 5.4.2. Retail Pharmacy
- 5.4.3. Online Pharmacy
- 5.5. Market Analysis, Insights and Forecast – By Country
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia pacific
- 5.5.4. Rest of World
- 6. North America Dermatitis Drugs Market Analysis, Insights and Forecast, 2014-2025
- 6.1. Key Findings / Summary
- 6.2. Market Analysis – By Drug Class
- 6.2.1. Calcineurin Inhibitors
- 6.2.2. PDE4 Inhibitors
- 6.2.3. Corticosteroids
- 6.2.4. Biologics
- 6.2.5. Others
- 6.3. Market Analysis – By Disease Indication
- 6.3.1. Atopic Dermatitis
- 6.3.2. Contact Dermatitis
- 6.3.3. Others
- 6.4. Market Analysis – By Distribution Channel
- 6.4.1. Hospital Pharmacy
- 6.4.2. Retail Pharmacy
- 6.4.3. Online Pharmacy
- 6.5. Market Analysis – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. Europe Dermatitis Drugs Market Analysis, Insights and Forecast, 2014-2025
- 7.1. Key Findings / Summary
- 7.2. Market Analysis – By Drug Class
- 7.2.1. Calcineurin Inhibitors
- 7.2.2. PDE4 Inhibitors
- 7.2.3. Corticosteroids
- 7.2.4. Biologics
- 7.2.5. Others
- 7.3. Market Analysis – By Disease Indication
- 7.3.1. Atopic Dermatitis
- 7.3.2. Contact Dermatitis
- 7.3.3. Others
- 7.4. Market Analysis – By Distribution Channel
- 7.4.1. Hospital Pharmacy
- 7.4.2. Retail Pharmacy
- 7.4.3. Online Pharmacy
- 7.5. Market Analysis – By Country
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
- 8. Asia pacific Dermatitis Drugs Market Analysis, Insights and Forecast, 2014-2025
- 8.1. Key Findings / Summary
- 8.2. Market Analysis – By Drug Class
- 8.2.1. Calcineurin Inhibitors
- 8.2.2. PDE4 Inhibitors
- 8.2.3. Corticosteroids
- 8.2.4. Biologics
- 8.2.5. Others
- 8.3. Market Analysis – By Disease Indication
- 8.3.1. Atopic Dermatitis
- 8.3.2. Contact Dermatitis
- 8.3.3. Others
- 8.4. Market Analysis – By Distribution Channel
- 8.4.1. Hospital Pharmacy
- 8.4.2. Retail Pharmacy
- 8.4.3. Online Pharmacy
- 8.5. Market Analysis – By Country
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
- 9. Rest of World Dermatitis Drugs Market Analysis, Insights and Forecast, 2014-2025
- 9.1. Key Findings / Summary
- 9.2. Market Analysis – By Drug Class
- 9.2.1. Calcineurin Inhibitors
- 9.2.2. PDE4 Inhibitors
- 9.2.3. Corticosteroids
- 9.2.4. Biologics
- 9.2.5. Others
- 9.3. Market Analysis – By Disease Indication
- 9.3.1. Atopic Dermatitis
- 9.3.2. Contact Dermatitis
- 9.3.3. Others
- 9.4. Market Analysis – By Distribution Channel
- 9.4.1. Hospital Pharmacy
- 9.4.2. Retail Pharmacy
- 9.4.3. Online Pharmacy
- 9.5. Market Analysis – By Country
- 10. Competitive Analysis
- 10.1. Key Industry Developments
- 10.2. Global Market Share Analysis (2017)
- 10.3. Competition Dashboard
- 10.4. Comparative Analysis – Major Players
- 10.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 10.5.1. Valeant Pharmaceuticals
- 10.5.1.1. Overview,
- 10.5.1.2. Products & services,
- 10.5.1.3. SWOT analysis,
- 10.5.1.4. Recent developments,
- 10.5.1.5. strategies,
- 10.5.1.6. financials (based on availability)
- 10.5.2. Astellas Pharma US, Inc.
- 10.5.2.1. Overview,
- 10.5.2.2. Products & services,
- 10.5.2.3. SWOT analysis,
- 10.5.2.4. Recent developments,
- 10.5.2.5. strategies,
- 10.5.2.6. financials (based on availability)
- 10.5.3. Pfizer, Inc.
- 10.5.3.1. Overview,
- 10.5.3.2. Products & services,
- 10.5.3.3. SWOT analysis,
- 10.5.3.4. Recent developments,
- 10.5.3.5. strategies,
- 10.5.3.6. financials (based on availability)
- 10.5.4. Mylan
- 10.5.4.1. Overview,
- 10.5.4.2. Products & services,
- 10.5.4.3. SWOT analysis,
- 10.5.4.4. Recent developments,
- 10.5.4.5. strategies,
- 10.5.4.6. financials (based on availability)
- 10.5.5. Bayer AG
- 10.5.5.1. Overview,
- 10.5.5.2. Products & services,
- 10.5.5.3. SWOT analysis,
- 10.5.5.4. Recent developments,
- 10.5.5.5. strategies,
- 10.5.5.6. financials (based on availability)
- 10.5.6. Allergan
- 10.5.6.1. Overview,
- 10.5.6.2. Products & services,
- 10.5.6.3. SWOT analysis,
- 10.5.6.4. Recent developments,
- 10.5.6.5. strategies,
- 10.5.6.6. financials (based on availability)
- 10.5.7. LEO Pharma
- 10.5.7.1. Overview,
- 10.5.7.2. Products & services,
- 10.5.7.3. SWOT analysis,
- 10.5.7.4. Recent developments,
- 10.5.7.5. strategies,
- 10.5.7.6. financials (based on availability)
- 10.5.8. Regeneron Pharmaceuticals, Inc.
- 10.5.8.1. Overview,
- 10.5.8.2. Products & services,
- 10.5.8.3. SWOT analysis,
- 10.5.8.4. Recent developments,
- 10.5.8.5. strategies,
- 10.5.8.6. financials (based on availability)
- 10.5.9. Anacor Pharmaceuticals, Inc.
- 10.5.9.1. Overview,
- 10.5.9.2. Products & services,
- 10.5.9.3. SWOT analysis,
- 10.5.9.4. Recent developments,
- 10.5.9.5. strategies,
- 10.5.9.6. financials (based on availability)
- 11. Strategic Recommendations "
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
